

2019/12/3	児嶋	DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 study.	Haematologica	2019	24-Oct	Epub
	佐藤	Glitteritnib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.	N Engl J Med	2019	381(18)	1728-1740)
2019/12/10	新山	Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade.	Blood	2019	134(17)	1406-1414
	波多	Invariant patterns of clonal succession determine specific clinical features of myelodysplastic syndromes.	Nat Commun	2019	10(1)	5386
2019/12/17	宮崎/千綿	ASH報告会				
	長井	Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy.	Blood	2019	134(24)	:2149-2158
2019/12/24	藤岡	Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level	Nature med	2019	25	103-110
	澤山	Posttransplant cyclophosphamide vs cyclosporin A and methotrexate as GVHD prophylaxis in matched sibling transplantation.	Blood Adv	2019	3(21)	3351-3359
2020/1/7	今泉	Reproducing the molecular subclassification of peripheral T-cell lymphoma-NOS by immunohistochemistry.	Blood	2019	134(24)	2159-2170
	坂本	Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.	N Engl J Med	2019	381(24)	2315-2326
2020/1/14	千綿	Arterial thromboembolic events preceding the diagnosis of cancer in older persons.	Blood	2019	133(8)	781-789
	安東	Functional Enhancers Shape Extrachromosomal Oncogene Amplifications.	Cell	2019	179(6)	1330-1341
2020/1/21	クリクラ生	Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial	Lancet	2020	394(10216)	2271-2281
	長井	Daratumumabの臨床試験についての説明				
2020/1/28	千綿	Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia.	Cancer	2020	126(1)	67-75
	桐野	Allo-HSCT in transplant-naïve patients with Hodgkin lymphoma: a single-arm, multicenter study.	Blood Adv	2019	3(24)	4262-4270
2020/2/4	藤岡	造血幹細胞移植学会予行				
2020/2/18	クリクラ生	Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.	J Clin Oncol	2020	38(2)	155-165
	宮崎	MLLT3 governs human haematopoietic stem-cell self-renewal and engraftment.	Nature	2019	576(7786)	281-286
2020/2/25	山田	Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease.	J Clin Oncol	2019	20-Dec	Epub
	佐藤	Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.	N Engl J Med	2020	382(2)	140-151
2020/3/3	児嶋	Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia.	J Clin Oncol	2020	38(5)	415-422
	波多	Impact of somatic mutations in myelodysplastic patients with isolated partial or total loss of chromosome 7.	Leukemia	2020	17-Feb	Epub
2020/3/10	新山	Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study.	J Clin Oncol	2020	21-Feb	Epub
	長井	Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia.	Blood	2020	135(10)	713-723
2020/3/17	藤岡	Cancer spectrum and outcomes in the Mendelian short telomere syndromes.	Blood	2020	19-Feb	Epub
	澤山	Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study.	Bone Marrow Transplant	2020	55(3)	641-648
2020/3/24	今泉	令和元年度第2回JCOG合同班会議報告				
	坂本	Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia.	Blood	2020	135(5)	371-380
2019/3/31	桐野	A Phase 1 Study of Azacitidine With High-Dose Cytarabine and Mitoxantrone in High-Risk Acute Myeloid Leukemia.	Blood Adv	2020	4(4)	599-606
	安東	Vitamin B6 Addiction in Acute Myeloid Leukemia	Cancer Cell	2020	37(1)	71-84.e7